Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Carmen Bozic"'
Autor:
Tuan Dong-Si, Amy Gangadharan, James D. McIninch, Madé Wenten, Thomas Weber, Sarah Gheuens, Nancy Richert, Gary Bloomgren, Jeffrey Philip, Sandra Richman, Carmen Bozic, David B. Clifford, Shoibal Datta
Publikováno v:
Journal of Neurovirology
Natalizumab, a highly effective therapy for relapsing-remitting multiple sclerosis, is associated with a risk of progressive multifocal leukoencephalopathy (PML). The objective of this analysis was to examine factors predicting survival in a large na
Publikováno v:
European Journal of Neurology. 21:299-304
Background and purpose Progressive multifocal leukoencephalopathy (PML) is caused by reactivation of JC virus (JCV) infection due to combined host and viral factors. Anti-JCV antibodies provide a means to assess JCV exposure and stratify PML risk. Th
Autor:
James V. Scanlon, Meena Subramanyam, Tatiana Plavina, Alfred Sandrock, Gary Bloomgren, Sandra Richman, Amy Natarajan, Carmen Bozic
Publikováno v:
Annals of Neurology. 70:742-750
Objective: A study was undertaken to define the prevalence of anti-JC virus (JCV) antibodies in multiple sclerosis (MS) patients and to evaluate the analytical false-negative rate of a 2-step anti-JC virus antibody assay. Methods: STRATIFY-1 is an on
Autor:
Gerald G. Krueger, Mohamed Darif, Kim A. Papp, Bernard S. Goffe, Marianne T. Sweetser, Barry Ticho, Carmen Bozic, Sophia Lee, David Gratton
Publikováno v:
Clinical Therapeutics. 27:1912-1921
Background: Information on longer-term safety andtolerability is needed to confidently prescribe alefacept therapy for chronic plaque psoriasis beyond 1 or 2 courses. Objective: The aim of this work was to further examine the safety profile of alefac
Publikováno v:
New England Journal of Medicine. 368:1659-1661
To the Editor: In the letters from Ermis et al.1 and van Oosten et al.2 published in this issue of the Journal, progressive multifocal leukoencephalopathy (PML) is reported in two patients with psoriasis who were being treated with Fumaderm (Biogen I
Autor:
Sarah Gheuens, Madé Wenten, Jeffrey Philip, Mike P. Wattjes, Tuan Dong-Si, Nancy Richert, Shoibal Datta, Gary Bloomgren, Sandra Richman, Carmen Bozic, James D. McIninch
Publikováno v:
Dong-Si, T, Richman, S, Wattjes, M P, Wenten, M, Gheuens, S, Philip, J, Datta, S, McIninch, J, Bozic, C, Bloomgren, G & Richert, N 2014, ' Outcome and survival of asymptomatic PML in natalizumab-treated MS patients ', Annals of Clinical and Translational Neurology, vol. 1, no. 10, pp. 755-764 . https://doi.org/10.1002/acn3.114
Annals of Clinical and Translational Neurology
Annals of Clinical and Translational Neurology, 1(10), 755-764. John Wiley and Sons Ltd
Annals of Clinical and Translational Neurology
Annals of Clinical and Translational Neurology, 1(10), 755-764. John Wiley and Sons Ltd
Objective As of 3 September 2013, 399 cases of natalizumab-associated progressive multifocal leukoencephalopathy (PML) were confirmed in multiple sclerosis (MS) patients. We evaluated outcomes of natalizumab-treated MS patients who were asymptomatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1469d66535118335ff823a97753ebc3
https://research.vumc.nl/en/publications/e7874827-aa2f-40b1-a80c-60d281c73fc1
https://research.vumc.nl/en/publications/e7874827-aa2f-40b1-a80c-60d281c73fc1
Autor:
Sophia Lee, Sandra Richman, Meena Subramanyam, Carmen Bozic, Susan Goelz, James V. Scanlon, Amy Natarajan, Tatiana Plavina, Gary Bloomgren, Christophe Hotermans, Alfred Sandrock
Publikováno v:
The New England journal of medicine. 366(20)
Progressive multifocal leukoencephalopathy (PML) is associated with natalizumab treatment. We quantified the risk of PML in patients with multiple sclerosis, according to the presence or absence of three risk factors: positive status with respect to
Publikováno v:
Inflammatory Bowel Diseases. 17:S56-S57
Publikováno v:
Annals of Neurology. 67:271-272
Publikováno v:
Annals of Neurology. 66:261-262